Healthcare · Biotechnology
Price
$11.61
Market Cap
$270.9M
Employees
161
Beta
-0.09
Avg Volume
100,656
CEO
Lynn Seely
Business Description
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Business History
Price Overview
Last updated: Jun 27, 2026 10:07am (just now)$11.61
-0.88 (-7.05%)
Day Range
$11.52 – $12.67
52-Week Range
$8.63 – $45.00
50-Day MA
$17.37
200-Day MA
$20.77
Volume
1,662,245.00
Analyst Price Targets
Low
$45.00
Consensus
$47.00
High
$49.00
(8 analysts)
Share Structure
Outstanding
23,334,087.00
Float
13,920,320.00
Free Float
59.7%
Normal free float
— 59.7% of shares trade freely, ~40.3% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.72
Stock Price: $11.61
EPS (Diluted): -16.06
EPS (Diluted): -16.06
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.12
Stock Price: $11.61
Total Equity: $248.20M
Shares: 17,093,000
Total Equity: $248.20M
Shares: 17,093,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.96
Market Cap: $270.91M
Total Debt: $0.00
Cash: $60.18M
EBITDA: -$262.91M
Total Debt: $0.00
Cash: $60.18M
EBITDA: -$262.91M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$516.9M
Market Cap: $270.91M
Total Debt: $0.00
Cash: $60.18M
Total Debt: $0.00
Cash: $60.18M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
14,614.52
Stock Price: $11.61
Revenue: $36,000
Shares: 17,093,000
Revenue: $36,000
Shares: 17,093,000
EV/Sales (Total value vs revenue — works when P/E can't)
API14,359.32
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
-31,952.8%
Gross Profit: -$11.50M
Revenue: $36,000
Revenue: $36,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-566,038.9%
Operating Income: -$203.77M
Revenue: $36,000
Revenue: $36,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-762,355.6%
Net Income: -$274.45M
Revenue: $36,000
Revenue: $36,000
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-85.7%
Net Income: -$274.45M
Total Equity: $248.20M
Total Equity: $248.20M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-59.4%
Operating Income: -$203.77M
Tax Rate: 0.0%
Equity: $248.20M
Total Debt: $0.00
Cash: $60.18M
Tax Rate: 0.0%
Equity: $248.20M
Total Debt: $0.00
Cash: $60.18M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
5.28
Current Assets: $260.94M
Current Liabilities: $49.41M
Current Liabilities: $49.41M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $248.20M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $248.20M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.00
Revenue: $36,000
Shares: 17,093,000
Shares: 17,093,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$14.52
Total Equity: $248.20M
Shares: 17,093,000
Shares: 17,093,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-8.82
Operating CF: -$150.02M
CapEx: -$780,000
Shares: 17,093,000
CapEx: -$780,000
Shares: 17,093,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $11.61
Stock Price: $11.61
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$274.45M
Net Income: -$274.45M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares LYEL against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $10.7M | $84.7M | $130,000 | $61,000 | $36,000 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $11.5M |
| Gross Profit | $10.7M | $84.7M | $130,000 | $61,000 | -$11.5M |
| Operating Expenses | $225.4M | $271.7M | $247.1M | $358.8M | $192.3M |
| Operating Income | -$214.8M | -$187.1M | -$247.0M | -$358.8M | -$203.8M |
| Net Income | -$250.2M | -$183.1M | -$234.6M | -$343.0M | -$274.4M |
| EBITDA | -$236.6M | -$165.1M | -$214.4M | -$200.6M | -$262.9M |
| EPS | $-1.03 | $-0.74 | $-0.93 | $-1.31 | $-16.06 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $293.8M | $123.6M | $145.6M | $105.6M | $60.2M |
| Total Current Assets | $626.3M | $651.3M | $554.7M | $379.6M | $260.9M |
| Total Assets | $1.1B | $937.6M | $750.0M | $490.9M | $340.1M |
| Current Liabilities | $46.7M | $37.0M | $34.5M | $53.8M | $49.4M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $197.6M | $104.3M | $95.1M | $108.0M | $91.9M |
| Total Equity | $929.8M | $833.3M | $655.0M | $382.8M | $248.2M |
| Retained Earnings | -$584.4M | -$767.5M | -$1.0B | -$1.3B | -$1.6B |
Cash Flow (Annual)
Last updated: Jun 24, 2026 2:04pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$126.2M | -$169.6M | -$163.7M | -$162.4M | -$150.0M |
| Capital Expenditure | -$65.5M | -$24.3M | -$2.7M | $-464,000 | $-780,000 |
| Free Cash Flow | -$191.8M | -$193.8M | -$166.4M | -$162.9M | -$150.8M |
| Acquisitions (net) | $673.5M | $0 | $0 | -$31.3M | -$41.2M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $153.4M | -$170.3M | $22.1M | -$38.6M | -$45.5M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$9.4M $9.4M – $9.4M
|
$56.7M $56.7M – $56.7M
|
$190.2M $190.2M – $190.2M
|
$280.0M $280.0M – $280.0M
|
| EBITDA |
-$9.4M -$9.4M – -$9.4M
|
-$56.7M -$56.7M – -$56.7M
|
-$190.2M -$190.2M – -$190.2M
|
-$280.0M -$280.0M – -$280.0M
|
| Net Income |
-$136.6M -$178.9M – -$94.3M
|
-$121.9M -$151.4M – -$92.3M
|
-$87.4M -$87.4M – -$87.4M
|
-$69.5M -$69.5M – -$69.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +695.1% | -99.8% | -53.1% | -41.0% |
| Gross Profit Growth | +695.1% | -99.8% | -53.1% | -18,957.4% |
| Operating Income Growth | +12.9% | -32.0% | -45.2% | +43.2% |
| Net Income Growth | +26.8% | -28.1% | -46.2% | +20.0% |
| EBITDA Growth | +30.2% | -29.9% | +6.4% | -31.0% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Innovative Cellular Therapeutics Holdings Ltd | J-Other | 66,500.00 | $0.00 | $0 |
| 2026-05-18 | Innovative Cellular Therapeutics Holdings Ltd | 0.00 | $0.00 | $0 | |
| 2026-05-11 | Seely Lynn | S-Sale | 388.00 | $18.91 | $7,337 |
| 2026-05-11 | Lee Gary K. | S-Sale | 130.00 | $18.92 | $2,460 |
| 2026-05-11 | Hill Stephen J. | S-Sale | 89.00 | $18.92 | $1,684 |
| 2026-05-11 | Bulis Veronica Sanchez | S-Sale | 217.00 | $18.91 | $4,103 |
| 2026-06-10 | RIEFLIN WILLIAM JL | A-Award | 9,250.00 | $13.22 | $122,285 |
| 2026-06-10 | Ramachandra Sumant | A-Award | 9,250.00 | $13.22 | $122,285 |
| 2026-06-10 | NABEL ELIZABETH G | A-Award | 9,250.00 | $13.22 | $122,285 |
| 2026-06-10 | Klausner Richard | A-Award | 9,250.00 | $13.22 | $122,285 |
| 2026-06-10 | FRIEDMAN CATHY | A-Award | 9,250.00 | $13.22 | $122,285 |
| 2026-06-10 | BRAWLEY OTIS W | A-Award | 9,250.00 | $13.22 | $122,285 |
| 2026-06-10 | Bachleda Mark | A-Award | 9,250.00 | $13.22 | $122,285 |
| 2026-06-10 | Shook David | S-Sale | 1,977.00 | $12.64 | $24,989 |
| 2026-03-09 | Shah Smital | A-Award | 140,000.00 | $25.50 | $3.6M |
| 2026-03-09 | Shah Smital | 0.00 | $0.00 | $0 | |
| 2026-03-06 | ARCH Venture Partners IX, LLC | P-Purchase | 488,090.00 | $25.61 | $12.5M |
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | P-Purchase | 488,090.00 | $25.61 | $12.5M |
| 2026-02-11 | Seely Lynn | S-Sale | 7,455.00 | $23.39 | $174,372 |
| 2026-02-11 | Hill Stephen J. | S-Sale | 1,236.00 | $23.39 | $28,910 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for LYEL — it's generated by the pipeline (
market-narrative step).
No community reviews yet for LYEL.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30